2. UroToday Home
  3. Video Lectures

Clinical Trials For My Patients - Prostate Cancer Videos

Comparing Industry-Sponsored and Investigator-Initiated Trials in Genitourinary Oncology - Srikala Sridhar
March 7, 2025
Details
Urologic Oncology Clinical Trials: Size, Scope, and Impact - Kristian Stensland
July 11, 2024
Details
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
June 17, 2024
Details
Moonshot Initiative Funds Study on PSA-Based Risk-Stratified Prostate Cancer Screening - Siobhan Sutcliffe
May 20, 2024
Details
The Southern California Research Forum: Advancing GU Cancer Care - Monty Pal & Rana McKay
February 21, 2024
Details
Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term ADT (METANOVA)
February 6, 2024
Details
ESCAPE TRIAL - Evaluation of PSMA PET-CT in Active Surveillance for Prostate CancEr
February 6, 2024
Details
INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala
November 15, 2023
Details
LuTectomy Study Shows Promise: Targeted Radiation Safe Before Prostate Cancer Surgery - Michael Hofman & Renu Eapen
November 13, 2023
Details
The ECLIPSE Phase III Trial of Lutetium PSMA-I&T Shows Promise in Advanced Prostate Cancer Treatment - Emmanuel Antonarakis
April 12, 2023
Details
Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA - Jones Nauseef
March 22, 2023
Details
Phase II Trial of Salvage Radiation Therapy for Prostate Cancer in Four Weeks Versus Five Days (SHORTER)
March 9, 2023
Details
Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
March 9, 2023
Details
NRG-GU 010 Phase III Trial: Tailored Prostate Cancer Treatment Based on Decipher Risk Score (GUIDANCE) PART 3
March 9, 2023
Details
NRG-GU 010 Phase III Trial: Tailored Prostate Cancer Treatment Based on Decipher Risk Score (GUIDANCE) PART 2
March 9, 2023
Details
NRG-GU 010 Phase III Trial: Tailored Prostate Cancer Treatment Based on Decipher Risk Score (GUIDANCE) PART 1
March 9, 2023
Details
Safety and Feasibility of a Shorter Course of Radiation Therapy for Men with Low or Intermediate Risk Prostate Cancer (FORT)
March 9, 2023
Details
The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
March 4, 2023
Details
LuTectomy, a Single-Arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Radical Prostatectomy - Declan Murphy & Renu Eapen
July 5, 2022
Details
Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence - UroToday Journal Club - Christopher Wallis & Zachary Klaassen
April 22, 2022
Details
Sabizabulin in Phase 1b/2 Clinical Trials of Men With Metastatic Castration-Resistant Prostate Cancer Who Progressed on Androgen Receptor-Targeting Agents - Mark Markowski
April 14, 2022
Details
Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore
March 27, 2022
Details
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng
March 10, 2022
Details
ARANOTE - Darolutamide in Addition to ADT Vs. ADT in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - Fred Saad
March 10, 2022
Details
Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski
October 31, 2021
Details
A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone
October 31, 2021
Details
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
October 15, 2021
Details
Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer – Robert Dreicer
September 28, 2021
Details
Single Priming Dose of 177Lu-PSMA-617 Followed by Pembrolizumab in mCRPC in a Phase 1b Trial - Rahul Aggarwal
August 27, 2021
Details
Talazoparib for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations (TALAPRO-1) Journal Club - Christopher Wallis & Zachary Klaassen
August 11, 2021
Details
Differences in the Pattern of and the Response to Treatment Not Just Race - Elisabeth Heath
June 27, 2021
Details
Evaluating the Benefit of Rucaparib and Enzalutamide Combination Therapy Vs. Enzalutamide Alone for the Treatment of mCRPC - the Phase III CASPAR Trial - Arpit Rao
March 8, 2021
Details
Intensive Androgen Deprivation in High-Risk Biochemically Recurrent Prostate Cancer Patients - Alliance Foundation Trial (AFT19) - Rahul Aggarwal
February 23, 2021
Details
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
February 25, 2020
Details
The DORA Trial, Comparing Overall Survival in Patients Treated with Docetaxel vs. Docetaxel plus Radium-223 - Michael Morris
November 20, 2019
Details
Count Me In! The Metastatic Prostate Cancer Project - Eliezer Van Allen
September 16, 2019
Details
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
August 2, 2019
Details
Current Landscape of Prostate Cancer Clinical Trials - Alliance Cooperative Group - Michael J. Morris
July 30, 2019
Details
STARTAR Trial: Systemic Therapy in Salvage Setting for Prostate Cancer- Tian Zhang
November 28, 2018
Details